MX2014012535A - Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos. - Google Patents

Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos.

Info

Publication number
MX2014012535A
MX2014012535A MX2014012535A MX2014012535A MX2014012535A MX 2014012535 A MX2014012535 A MX 2014012535A MX 2014012535 A MX2014012535 A MX 2014012535A MX 2014012535 A MX2014012535 A MX 2014012535A MX 2014012535 A MX2014012535 A MX 2014012535A
Authority
MX
Mexico
Prior art keywords
chemotherapeutics
combination therapy
mif antibodies
mif
antibodies
Prior art date
Application number
MX2014012535A
Other languages
English (en)
Inventor
Friedrich Scheiflinger
Randolf Kerschbaumer
Hartmut Ehrlich
Original Assignee
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48625989&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014012535(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Healthcare Sa filed Critical Baxter Healthcare Sa
Publication of MX2014012535A publication Critical patent/MX2014012535A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

La presente invención pertenece a anticuerpos anti-MIF, en particular a su uso en combinación con terapéuticos, es decir, quimioterapéuticos, en el tratamiento de cáncer.
MX2014012535A 2012-04-16 2013-04-16 Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos. MX2014012535A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261624964P 2012-04-16 2012-04-16
US201261668932P 2012-07-06 2012-07-06
US201361778094P 2013-03-12 2013-03-12
PCT/EP2013/057894 WO2013156473A1 (en) 2012-04-16 2013-04-16 Combination therapy of anti-mif antibodies and chemotherapeutics

Publications (1)

Publication Number Publication Date
MX2014012535A true MX2014012535A (es) 2015-04-10

Family

ID=48625989

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014012535A MX2014012535A (es) 2012-04-16 2013-04-16 Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos.

Country Status (16)

Country Link
US (1) US20150071942A1 (es)
EP (2) EP2838561A1 (es)
JP (2) JP2015514735A (es)
KR (2) KR20160049047A (es)
CN (2) CN106139143A (es)
AU (1) AU2013202693B2 (es)
BR (1) BR112014025855A8 (es)
CA (1) CA2869990A1 (es)
CL (2) CL2014002788A1 (es)
CO (1) CO7131377A2 (es)
HK (1) HK1206985A1 (es)
IL (2) IL235038A0 (es)
MX (1) MX2014012535A (es)
NZ (1) NZ628363A (es)
RU (2) RU2016117260A (es)
WO (1) WO2013156473A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105452867A (zh) 2012-07-10 2016-03-30 巴克斯特保健股份有限公司 抗-mif的免疫组织化学
AU2015206178A1 (en) * 2014-01-03 2016-07-07 Baxalta GmbH Anti-MIF immunohistochemistry
EP3277718B1 (en) 2015-03-31 2021-03-24 Baxalta GmbH Dosage regimen for anti-mif antibodies
WO2016184886A1 (en) 2015-05-18 2016-11-24 Baxalta GmbH Anti-mif antibodies in the treatment of cancers containing mutant tp53 and/or mutant ras

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1741779A3 (en) * 1993-05-17 2010-03-24 The Picower Institute For Medical Research Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine mediated toxicity
US6080407A (en) * 1993-05-17 2000-06-27 The Picower Institute For Medical Research Diagnostic assays for MIF
US6774227B1 (en) * 1993-05-17 2004-08-10 Cytokine Pharmasciences, Inc. Therapeutic uses of factors which inhibit or neutralize MIF activity
AU2001238677A1 (en) * 2000-02-28 2001-09-12 Idec Pharmaceuticals Corporation Method for preparing anti-mif antibodies
MXPA05007382A (es) * 2003-01-10 2005-11-23 Threshold Pharmaceuticals Inc Tratamiento de cancer con 2-desoxiglucosa.
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
CN101010100A (zh) * 2004-07-02 2007-08-01 纽泰克医药有限公司 癌症的治疗方法
SG153825A1 (en) * 2005-12-16 2009-07-29 Ibc Pharmaceuticals Inc Multivalent immunoglobulin-based bioactive assemblies
CN100457895C (zh) * 2006-05-24 2009-02-04 中国科学院生物物理研究所 鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用
US20090220521A1 (en) * 2008-01-04 2009-09-03 Randolf Kerschbaumer Anti MIF Antibodies
CA2787074A1 (en) * 2010-01-19 2011-07-28 Immunomedics, Inc. Novel antibodies that target the insulin-like growth factor type i receptor (igf-1r)
US9465037B2 (en) * 2011-10-07 2016-10-11 Baxalta Incorporated Characterization of CHO-MIF gene and protein, and use thereof
JP2014530360A (ja) * 2011-10-07 2014-11-17 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ 診断マーカーとしてのｏｘＭＩＦ

Also Published As

Publication number Publication date
AU2013202693B2 (en) 2015-01-22
AU2013202693A1 (en) 2013-10-31
CL2016001327A1 (es) 2017-01-06
RU2014145887A (ru) 2016-06-10
RU2016117260A (ru) 2018-10-23
KR20160049047A (ko) 2016-05-04
US20150071942A1 (en) 2015-03-12
HK1206985A1 (en) 2016-01-22
KR20150027048A (ko) 2015-03-11
JP2016175918A (ja) 2016-10-06
NZ628363A (en) 2017-02-24
EP2838561A1 (en) 2015-02-25
CN104812411A (zh) 2015-07-29
IL245604A0 (en) 2016-06-30
CL2014002788A1 (es) 2015-02-06
IL235038A0 (en) 2014-12-31
BR112014025855A2 (es) 2017-06-20
BR112014025855A8 (pt) 2017-07-25
WO2013156473A1 (en) 2013-10-24
CO7131377A2 (es) 2014-12-01
JP2015514735A (ja) 2015-05-21
RU2016117260A3 (es) 2018-10-23
EP3064221A1 (en) 2016-09-07
CN106139143A (zh) 2016-11-23
CA2869990A1 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
EA201500314A1 (ru) Лекарственные формы энзалутамида
EA201400178A1 (ru) Лечение рака молочной железы
MX2016004678A (es) Composiciones para el tratamiento del cancer.
IL242386B (en) Use of Aribolin and Lavetinib as a combination therapy for cancer treatment
TW201611843A (en) Methods of treatment with arginine deiminase
PH12018502570A1 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
MX2015011899A (es) Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
IL239007A0 (en) Use of Aribolin to treat breast cancer
PH12015501071A1 (en) Combination therapy of anti-her3 antibodies
MX2015014046A (es) Combinaciones de farmacos para tratar cancer.
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
MX2023007706A (es) Nanoparticulas para su uso como vacuna terapeutica.
MX2014012535A (es) Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos.
GB201310909D0 (en) Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
AU346747S (en) Basin
EP2744786A4 (en) SUBSTITUTED 2-IMIDAZOLIDINONE AND 2-IMIDAZOLONE AND THEIR USE IN THE TREATMENT OF CANCER
MX2014014839A (es) Terapias sinergicas de cannabidiol con hipotermia para neuroproteccion.
AU345245S (en) Muffler
IN2014KN01772A (es)
EA201690709A1 (ru) Применение одипарцила в лечении мукополисахаридоза
MX360885B (es) Nuevas composiciones antifungicas.
CO7131362A2 (es) Terapia de combinación de anticuerpos anti-mif y glucocorticoides